Advertisement

Pharmacy

Home Pharmacy

Dove, TRESemmé Dry Shampoos Recalled Due to Possible Carcinogen

Propellant used in the products appears to be the source of the elevated benzene levels

Few patients have conversations with providers about the cost of glaucoma medications

Few Patients, Providers Discuss Costs of Glaucoma Medications

Authors say these discussions are important, as cost is a barrier to treatment adherence

mRNA Vaccines Effectively Prevent SARS-CoV-2 in Adults in Real-World Setting

For those with SARS-CoV-2 infection, vaccinated participants had lower mean viral load, risk of febrile symptoms, illness duration

An artificially intelligent computer system

SABCS: Artificial Intelligence May Aid Doctors in Breast Cancer Care

'Watson Oncology' agreed with doctors 90 percent of the time in many cases, researchers find

Hair Regrowth Seen in Alopecia With Methotrexate + Prednisone

About 31 percent of patients with recalcitrant alopecia areata totalis or universalis had complete hair regrowth

Flu vaccination is underused in high-risk patients but is associated with reduced rates of cardiovascular events among patients who do receive it

Flu Vaccination in High-Risk Groups May Reduce CV Events

Hospitalized patients at high risk who are vaccinated have lower rates of MI, TIA, cardiac arrest, death
Lumacaftor/ivacaftor treatment is generally safe and well tolerated for children aged 2 to 5 years with cystic fibrosis homozygous for the F508del-CFTR mutation

Drug Combo Tolerated in Younger Children With Cystic Fibrosis

Lumacaftor/ivacaftor safe in children ages 2 to 5 with cystic fibrosis homozygous for F508del-CFTR
The odds of surviving cardiac arrest seem higher for patients who've been taking statins

AHA: Survival Odds Up With Statins Before Cardiac Arrest

Those already taking statin medication more likely to be alive one year later
Certain sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists demonstrate significant cardiovascular (CV) benefit and should be used for reducing CV risk in patients with type 2 diabetes and atherosclerotic cardiovascular disease

Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk

Report provides guidance on reducing CV risk in patients with T2DM and atherosclerotic CV disease